FindTrial
Sign In

The effects of high-intersity atorvastatin therapy in acute coronary syndrome patients undergoing percutaneous coronary intervention

The effects of high-intersity atorvastatin therapy in acute coronary syndrome patients undergoing percutaneous coronary intervention

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012291
Enrollment
Unknown
Registered
2017-08-08
Start date
2015-04-16
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Interventions

Research Group:atorvastatin sequential reinforcement therapy
Control Group:regular dose of atorvastatin

Sponsors

Tangdu Hospital,Medical University of the Air Force (The former Fourth Military Medical University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. ACS hospitalized patients; 2. The patients who underwent PCI; 3. The patients who agreed to be followed up and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. There are contraindications to statins, such as active liver disease, statin allergy or intolerance, and the history of rhabdomyolysis caused by taking statins; 2. Other statins other than atorvastatin are used at discharge; 3. Cardiac function classification(NYHA)IV; 4. Malignant tumor; 5. Severe arrhythmia.

Design outcomes

Primary

MeasureTime frame
liver and renal function;Four items of blood lipids;echocardiography;Carotid vascular ultrasounel;electrocardiogram;—

Secondary

MeasureTime frame
Hypersensitivity C reactive protein;Cystatin C;—

Countries

China

Contacts

Public ContactHaiyan Wang

Tangdu Hospital, Medical University of the Air Force (The former Military Medical University)

whyzhh@fmmu.edu.cn+86 13892892920

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026